Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LACI-2
2016-002277-35Phase 3Unknown
- Sponsor
- University of Edinburgh
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cilostazol and isosorbide mononitrate in lacunar infarct and Cerebral Small Vessel Disease (CSVD) (4 arms), sponsored by University of Edinburgh. Primary endpoint: Feasibility of a prospective randomized trial. Status: unknown.
02
Drugs
cilostazolisosorbide mononitrate
03
Conditions
lacunar infarctCerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on 2016-002277-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002277-35.